Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Authors :: Kumar SK
Callander NS
Adekola K
Anderson LD Jr
Baljevic M
Baz R
Campagnaro E
Castillo JJ
Costello C
D'Angelo C
Derman B
Devarakonda S
Elsedawy N
Garfall A
Godby K
Hillengass J
Holmberg L
Htut M
Huff CA
Hultcrantz M
Kang Y
Larson S
Lee H
Liedtke M
Martin T
Omel J
Robinson T
Rosenberg A
Sborov D
Schroeder MA
Sherbenou D
Suvannasankha A
Valent J
Varshavsky-Yanovsky AN
Snedeker J
Kumar R
Source :: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2024 Jan; Vol. 22 (1D), pp. e240001.
Publication Year :: 2024
Abstract: The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.

Subjects :: Humans
Lymphoma, B-Cell
Waldenstrom Macroglobulinemia therapy
Waldenstrom Macroglobulinemia drug therapy

Full Text Access

Tools